RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

Demin Cai, Junjian Wang, Bei Gao, Jin Li, Feng Wu, June X. Zou, Jianzhen Xu, Yuqian Jiang, Hongye Zou, Zenghong Huang, Alexander D. Borowsky, Richard J. Bold, Primo N. Lara, Jian Jian Li, Xinbin Chen, Kit S. Lam, Ka Fai To, Hsing Jien Kung, Oliver Fiehn, Ruqian ZhaoRonald M. Evans, Hong Wu Chen

Research output: Contribution to journalArticle

Abstract

Tumor subtype-specific metabolic reprogrammers could serve as targets of therapeutic intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear receptor RORγ, compared to estrogen receptor-positive breast cancer. Genetic and pharmacological inhibition of RORγ reduces tumor cholesterol content and synthesis rate while preserving host cholesterol homeostasis. We demonstrate that RORγ functions as an essential activator of the entire cholesterol-biosynthesis program, dominating SREBP2 via its binding to cholesterol-biosynthesis genes and its facilitation of the recruitment of SREBP2. RORγ inhibition disrupts its association with SREBP2 and reduces chromatin acetylation at cholesterol-biosynthesis gene loci. RORγ antagonists cause tumor regression in patient-derived xenografts and immune-intact models. Their combination with cholesterol-lowering statins elicits superior anti-tumor synergy selectively in TNBC. Together, our study uncovers a master regulator of the cholesterol-biosynthesis program and an attractive target for TNBC.

Original languageEnglish (US)
Article number4621
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

biosynthesis
Biosynthesis
regulators
cholesterol
cancer
Cholesterol
Triple Negative Breast Neoplasms
breast
Tumors
tumors
Neoplasms
genes
Genes
acetylation
estrogens
Hydroxymethylglutaryl-CoA Reductase Inhibitors
homeostasis
Acetylation
chromatin
loci

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. / Cai, Demin; Wang, Junjian; Gao, Bei; Li, Jin; Wu, Feng; Zou, June X.; Xu, Jianzhen; Jiang, Yuqian; Zou, Hongye; Huang, Zenghong; Borowsky, Alexander D.; Bold, Richard J.; Lara, Primo N.; Li, Jian Jian; Chen, Xinbin; Lam, Kit S.; To, Ka Fai; Kung, Hsing Jien; Fiehn, Oliver; Zhao, Ruqian; Evans, Ronald M.; Chen, Hong Wu.

In: Nature communications, Vol. 10, No. 1, 4621, 01.12.2019.

Research output: Contribution to journalArticle

Cai, D, Wang, J, Gao, B, Li, J, Wu, F, Zou, JX, Xu, J, Jiang, Y, Zou, H, Huang, Z, Borowsky, AD, Bold, RJ, Lara, PN, Li, JJ, Chen, X, Lam, KS, To, KF, Kung, HJ, Fiehn, O, Zhao, R, Evans, RM & Chen, HW 2019, 'RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype', Nature communications, vol. 10, no. 1, 4621. https://doi.org/10.1038/s41467-019-12529-3
Cai, Demin ; Wang, Junjian ; Gao, Bei ; Li, Jin ; Wu, Feng ; Zou, June X. ; Xu, Jianzhen ; Jiang, Yuqian ; Zou, Hongye ; Huang, Zenghong ; Borowsky, Alexander D. ; Bold, Richard J. ; Lara, Primo N. ; Li, Jian Jian ; Chen, Xinbin ; Lam, Kit S. ; To, Ka Fai ; Kung, Hsing Jien ; Fiehn, Oliver ; Zhao, Ruqian ; Evans, Ronald M. ; Chen, Hong Wu. / RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{71d1da5dd5834b95b3a08416f082b815,
title = "RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype",
abstract = "Tumor subtype-specific metabolic reprogrammers could serve as targets of therapeutic intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear receptor RORγ, compared to estrogen receptor-positive breast cancer. Genetic and pharmacological inhibition of RORγ reduces tumor cholesterol content and synthesis rate while preserving host cholesterol homeostasis. We demonstrate that RORγ functions as an essential activator of the entire cholesterol-biosynthesis program, dominating SREBP2 via its binding to cholesterol-biosynthesis genes and its facilitation of the recruitment of SREBP2. RORγ inhibition disrupts its association with SREBP2 and reduces chromatin acetylation at cholesterol-biosynthesis gene loci. RORγ antagonists cause tumor regression in patient-derived xenografts and immune-intact models. Their combination with cholesterol-lowering statins elicits superior anti-tumor synergy selectively in TNBC. Together, our study uncovers a master regulator of the cholesterol-biosynthesis program and an attractive target for TNBC.",
author = "Demin Cai and Junjian Wang and Bei Gao and Jin Li and Feng Wu and Zou, {June X.} and Jianzhen Xu and Yuqian Jiang and Hongye Zou and Zenghong Huang and Borowsky, {Alexander D.} and Bold, {Richard J.} and Lara, {Primo N.} and Li, {Jian Jian} and Xinbin Chen and Lam, {Kit S.} and To, {Ka Fai} and Kung, {Hsing Jien} and Oliver Fiehn and Ruqian Zhao and Evans, {Ronald M.} and Chen, {Hong Wu}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-12529-3",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

AU - Cai, Demin

AU - Wang, Junjian

AU - Gao, Bei

AU - Li, Jin

AU - Wu, Feng

AU - Zou, June X.

AU - Xu, Jianzhen

AU - Jiang, Yuqian

AU - Zou, Hongye

AU - Huang, Zenghong

AU - Borowsky, Alexander D.

AU - Bold, Richard J.

AU - Lara, Primo N.

AU - Li, Jian Jian

AU - Chen, Xinbin

AU - Lam, Kit S.

AU - To, Ka Fai

AU - Kung, Hsing Jien

AU - Fiehn, Oliver

AU - Zhao, Ruqian

AU - Evans, Ronald M.

AU - Chen, Hong Wu

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Tumor subtype-specific metabolic reprogrammers could serve as targets of therapeutic intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear receptor RORγ, compared to estrogen receptor-positive breast cancer. Genetic and pharmacological inhibition of RORγ reduces tumor cholesterol content and synthesis rate while preserving host cholesterol homeostasis. We demonstrate that RORγ functions as an essential activator of the entire cholesterol-biosynthesis program, dominating SREBP2 via its binding to cholesterol-biosynthesis genes and its facilitation of the recruitment of SREBP2. RORγ inhibition disrupts its association with SREBP2 and reduces chromatin acetylation at cholesterol-biosynthesis gene loci. RORγ antagonists cause tumor regression in patient-derived xenografts and immune-intact models. Their combination with cholesterol-lowering statins elicits superior anti-tumor synergy selectively in TNBC. Together, our study uncovers a master regulator of the cholesterol-biosynthesis program and an attractive target for TNBC.

AB - Tumor subtype-specific metabolic reprogrammers could serve as targets of therapeutic intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear receptor RORγ, compared to estrogen receptor-positive breast cancer. Genetic and pharmacological inhibition of RORγ reduces tumor cholesterol content and synthesis rate while preserving host cholesterol homeostasis. We demonstrate that RORγ functions as an essential activator of the entire cholesterol-biosynthesis program, dominating SREBP2 via its binding to cholesterol-biosynthesis genes and its facilitation of the recruitment of SREBP2. RORγ inhibition disrupts its association with SREBP2 and reduces chromatin acetylation at cholesterol-biosynthesis gene loci. RORγ antagonists cause tumor regression in patient-derived xenografts and immune-intact models. Their combination with cholesterol-lowering statins elicits superior anti-tumor synergy selectively in TNBC. Together, our study uncovers a master regulator of the cholesterol-biosynthesis program and an attractive target for TNBC.

UR - http://www.scopus.com/inward/record.url?scp=85073168303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073168303&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-12529-3

DO - 10.1038/s41467-019-12529-3

M3 - Article

C2 - 31604910

AN - SCOPUS:85073168303

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4621

ER -